<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02365064</url>
  </required_header>
  <id_info>
    <org_study_id>682031-1_MA20150206</org_study_id>
    <nct_id>NCT02365064</nct_id>
  </id_info>
  <brief_title>CPAP vs ASV for Insomnia</brief_title>
  <acronym>P2P</acronym>
  <official_title>PAP to PAP: CPAP vs ASV for Insomnia Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ResMed</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ResMed</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will determine which of two different types of positive airway pressure (PAP&#xD;
      therapy) modes are more effective in reducing sleep breathing events in chronic insomnia&#xD;
      patients and in decreasing insomnia severity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presenting to the sleep clinic with a primary complaint of insomnia will be&#xD;
      potential participants for this study. Following diagnostic polysomnography (PSG) testing,&#xD;
      insomnia patients diagnosed with SDB and meeting inclusion criteria will be randomized to a&#xD;
      PAP treatment arm, CPAP or ASV. Participants will complete titration studies with their&#xD;
      assigned PAP mode and attend clinical follow-up appointments over a 14-16 week timeframe.&#xD;
      Titration PSG studies will assess PAP pressure needs to ensure that patients are receiving&#xD;
      optimal therapy at all times during this study. PAP adaptation barriers will be addressed as&#xD;
      they arise during the study, because it is important that participants are able to use PAP&#xD;
      therapy nightly during participation in this protocol. Baseline scores on insomnia severity,&#xD;
      sleep quality, subjective insomnia parameters, sleep related impairment, and quality of life&#xD;
      will be compared to outcome measures at the 4 month mark. Pre-treatment and post-treatment&#xD;
      objective improvements on sleep studies will also be compared including sleep breathing&#xD;
      indices, sleep consolidation indices, and objective data download information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insomnia Severity Index</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>Change in insomnia severity from baseline to 4 months as measured by subjective questionnaire. The Insomnia Severity Index has seven questions. The seven answers are added up for a total score. Scores range from 0 - 28. A higher score indicates a more severe degree of insomnia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Rating</measure>
    <time_frame>Baseline and 4 months</time_frame>
    <description>8 point Likert scale for change in subjective sleep quality from baseline to 4 months. Lower scores indicated more positive sleep quality. A score 0 indicates excellent sleep quality, and a score of 7 indicates very poor sleep quality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Morning Rating</measure>
    <time_frame>4 months</time_frame>
    <description>Change in subjective rating from baseline to 4 months based on a 0-100% scale. Lower scores equal a more positive experience</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Onset Latency</measure>
    <time_frame>4 months</time_frame>
    <description>Change in from baseline to 4 months in sleep onset time (minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wake After Sleep Onset (WASO)</measure>
    <time_frame>4 months</time_frame>
    <description>Change from baseline to 4 months for WASO in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>4 months</time_frame>
    <description>Change from baseline to 4 months in sleep efficiency (total sleep time/time in bed)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Insomnia</condition>
  <condition>Sleep-Disordered Breathing</condition>
  <arm_group>
    <arm_group_label>Continuous Positive Airway Pressure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adaptive Servo-Ventilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AirCurve 10 ASV</intervention_name>
    <description>Device is able to provide both ASV therapy and CPAP therapy modes.</description>
    <arm_group_label>Adaptive Servo-Ventilation</arm_group_label>
    <arm_group_label>Continuous Positive Airway Pressure</arm_group_label>
    <other_name>VPAP Adapt, AutoSet CS2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary complaint of insomnia when presenting at clinic&#xD;
&#xD;
          -  Diagnosis of moderate to severe insomnia through the Insomnia Severity Index (ISI)&#xD;
             with a score ≥ 15&#xD;
&#xD;
          -  Meet diagnostic criteria of Insomnia Disorder (per American Academy of Sleep Medicine)&#xD;
&#xD;
          -  Diagnosis of SDB, either OSA as determined by an AHI ≥ 5 events/hour or UARS with a&#xD;
             RDI ≥ 15 events/hour and AHI &lt; 5 events/hour&#xD;
&#xD;
          -  Naïve to treatment for sleep-disordered breathing (SDB), including CPAP, APAP, ASV;&#xD;
             mandibular repositioning devices (MRDs), and any other nasal or oral therapy with a&#xD;
             primary indication of treating SDB&#xD;
&#xD;
          -  Able to fully understand study information in English and sign informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary complaint of sleep-disordered breathing or issues with apneas during sleep&#xD;
&#xD;
          -  Severe respiratory disorder or severe sleep disorder such as restless leg syndrome&#xD;
             (RLS), idiopathic hypersomnia, or narcolepsy&#xD;
&#xD;
          -  BMI &gt; 30 kg/m2&#xD;
&#xD;
          -  Epworth Sleepiness Scale (ESS) score ≥ 10&#xD;
&#xD;
          -  Frequent napping behavior, such as a few times a week or more&#xD;
&#xD;
          -  Anticipated changes to start or stop sedative or psychotropic medications during the&#xD;
             course of the trial&#xD;
&#xD;
          -  Medical history of congestive heart failure (CHF) or other potentially unstable&#xD;
             cardiac disease as well as chronic lung diseases or other debilitating medical&#xD;
             conditions that manifest as more prominent in the patient's health compared to their&#xD;
             sleep complaints&#xD;
&#xD;
          -  Daily use of opiate medications&#xD;
&#xD;
          -  Known contraindications to PAP therapy as listed in the indication for use&#xD;
&#xD;
          -  Requires a CPAP (fixed) pressure &gt; 20 cm H2O&#xD;
&#xD;
          -  Inability to comply with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Krakow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sleep &amp; Human Health Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maimonides Sleep Arts &amp; Sciences</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <results_first_submitted>May 24, 2021</results_first_submitted>
  <results_first_submitted_qc>August 13, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2021</results_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 7, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT02365064/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Continuous Positive Airway Pressure</title>
          <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
        </group>
        <group group_id="P2">
          <title>Adaptive Servo-Ventilation</title>
          <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Included in ITT Analysis</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Patients met baseline exclusion requirem</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment intolerance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline information available for ITT</population>
      <group_list>
        <group group_id="B1">
          <title>Continuous Positive Airway Pressure</title>
          <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
        </group>
        <group group_id="B2">
          <title>Adaptive Servo-Ventilation</title>
          <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.95" lower_limit="39.14" upper_limit="50.76"/>
                    <measurement group_id="B2" value="45.89" lower_limit="40.26" upper_limit="51.52"/>
                    <measurement group_id="B3" value="45.44" lower_limit="41.51" upper_limit="49.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Insomnia Severity Index</title>
        <description>Change in insomnia severity from baseline to 4 months as measured by subjective questionnaire. The Insomnia Severity Index has seven questions. The seven answers are added up for a total score. Scores range from 0 - 28. A higher score indicates a more severe degree of insomnia.</description>
        <time_frame>Baseline and 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Positive Airway Pressure</title>
            <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
          <group group_id="O2">
            <title>Adaptive Servo-Ventilation</title>
            <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
        </group_list>
        <measure>
          <title>Insomnia Severity Index</title>
          <description>Change in insomnia severity from baseline to 4 months as measured by subjective questionnaire. The Insomnia Severity Index has seven questions. The seven answers are added up for a total score. Scores range from 0 - 28. A higher score indicates a more severe degree of insomnia.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.29" spread="6.57"/>
                    <measurement group_id="O2" value="13.21" spread="5.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality Rating</title>
        <description>8 point Likert scale for change in subjective sleep quality from baseline to 4 months. Lower scores indicated more positive sleep quality. A score 0 indicates excellent sleep quality, and a score of 7 indicates very poor sleep quality</description>
        <time_frame>Baseline and 4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Positive Airway Pressure</title>
            <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
          <group group_id="O2">
            <title>Adaptive Servo-Ventilation</title>
            <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality Rating</title>
          <description>8 point Likert scale for change in subjective sleep quality from baseline to 4 months. Lower scores indicated more positive sleep quality. A score 0 indicates excellent sleep quality, and a score of 7 indicates very poor sleep quality</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.00"/>
                    <measurement group_id="O2" value="1.65" spread="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Morning Rating</title>
        <description>Change in subjective rating from baseline to 4 months based on a 0-100% scale. Lower scores equal a more positive experience</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Positive Airway Pressure</title>
            <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
          <group group_id="O2">
            <title>Adaptive Servo-Ventilation</title>
            <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
        </group_list>
        <measure>
          <title>Global Morning Rating</title>
          <description>Change in subjective rating from baseline to 4 months based on a 0-100% scale. Lower scores equal a more positive experience</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.39" spread="20.03"/>
                    <measurement group_id="O2" value="24.33" spread="13.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Onset Latency</title>
        <description>Change in from baseline to 4 months in sleep onset time (minutes)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Positive Airway Pressure</title>
            <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
          <group group_id="O2">
            <title>Adaptive Servo-Ventilation</title>
            <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Onset Latency</title>
          <description>Change in from baseline to 4 months in sleep onset time (minutes)</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.09" spread="44.39"/>
                    <measurement group_id="O2" value="7.17" spread="26.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Wake After Sleep Onset (WASO)</title>
        <description>Change from baseline to 4 months for WASO in minutes</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Positive Airway Pressure</title>
            <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
          <group group_id="O2">
            <title>Adaptive Servo-Ventilation</title>
            <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
        </group_list>
        <measure>
          <title>Wake After Sleep Onset (WASO)</title>
          <description>Change from baseline to 4 months for WASO in minutes</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.72" spread="58.73"/>
                    <measurement group_id="O2" value="-0.12" spread="61.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Efficiency</title>
        <description>Change from baseline to 4 months in sleep efficiency (total sleep time/time in bed)</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Continuous Positive Airway Pressure</title>
            <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
          <group group_id="O2">
            <title>Adaptive Servo-Ventilation</title>
            <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.&#xD;
AirCurve 10 ASV: Device is able to provide both ASV therapy and CPAP therapy modes.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency</title>
          <description>Change from baseline to 4 months in sleep efficiency (total sleep time/time in bed)</description>
          <units>percentage of time in bed</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="16.68"/>
                    <measurement group_id="O2" value="-2.85" spread="16.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 months</time_frame>
      <desc>Participants were asked to report side effects commonly related to CPAP usage, including:&#xD;
Drying of the nose, mouth or throat, Nosebleed, Ear or sinus discomfort, Eye irritation, Skin rashes Participants may report multiple side effects</desc>
      <group_list>
        <group group_id="E1">
          <title>Continuous Positive Airway Pressure</title>
          <description>Continuous positive airway pressure (CPAP) intervention as active comparator. Provides a fixed pressure for both inspiration and expiration.</description>
        </group>
        <group group_id="E2">
          <title>Adaptive Servo-Ventilation</title>
          <description>Adaptive servo-ventilation (ASV) positive airway pressure as experimental intervention. Provides a higher pressure for inspiration and a lower pressure for expiration with changes in the pressure support level to meet a target minute ventilation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>mask leak</sub_title>
                <description>Mask leak is a common side effect to CPAP treatment, and can lead to dry mouth (from mask/ mouth leak), congestion, and eye irritation</description>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>dry mouth</sub_title>
                <description>Dry mouth is a common complaint usually caused by mask leak or mouth breathing while using PAP</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>mask related insomnia</sub_title>
                <description>Difficulty sleeping due to wearing a CPAP mask</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>mouth leak</sub_title>
                <description>Discomfort due to air leaking from the mouth during CPAP use</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>congestion</sub_title>
                <description>Nasal congestion due to CPAP use</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>nose tickle/ burn</sub_title>
                <description>Discomfort in nasal passages while using CPAP</description>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>aerophagia</sub_title>
                <description>Discomfort from swallowing air during CPAP use</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>eye irritation</sub_title>
                <description>Eye irritation due to mask leak (air leaking into eyes) during CPAP use</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin irritation</sub_title>
                <description>Skin irritation due to wearing a mask at night</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>skin crease from mask</sub_title>
                <description>Facial marks due to wearing a CPAP mask at night</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Barry Krakow</name_or_title>
      <organization>Sleep and Human Health Institute</organization>
      <phone>(505) 9987204</phone>
      <email>bkrakow@sleeptreatment.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

